
In a prospective study of 351 CHB patients with LLV, switching from entecavir (ETV) to tenofovir alafenamide (TAF) led to significantly higher virological response (75.3% vs. 11.4%) and ALT normalization (67.8% In vs. In 17.1 In % In) In at In 48 In weeks In (In p < 0.001). Renal function and lipid profiles were comparable. Switching to TAF is a more effective strategy than continuing ETV for CHB patients with LLV.
Like
Save
Share